Pragmatic trials, a step forward to assess cardiovascular efficacy of new  glucose-lowering agents.

IY9XDZ35W2 (Glucose); Hypoglycemic Agents; Humans; Glucose; Hypoglycemic Agents/therapeutic use; Diabetes Mellitus, Type 2/drug therapy; Cardiovascular System; Cardiovascular Diseases/prevention & control

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Language :

English

Title :

Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents.

Publication date :

September 2023

Journal title :

The Lancet Diabetes and Endocrinology

ISSN :

2213-8587

eISSN :

2213-8595

Publisher :

Elsevier, Nl

Volume :

Issue :

Pages :

626-627

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 31 August 2023

Statistics

Number of views

21 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Kanie, T, Mizuno, A, Takaoka, Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev, 10, 2021, CD013650.
Scheen, AJ, Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Brown, E, Heerspink, HJL, Cuthbertson, DJ, Wilding, JPH, SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398 (2021), 262–276.
Xie, Y, Bowe, B, Xian, H, Loux, T, McGill, JB, Al-Aly, Z, Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol, 2023 published online July 24. https://doi.org/10.1016/S2213-8587(23)00171-7.
Giugliano, D, Longo, M, Signoriello, S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol, 21, 2022, 42.
Grenet, G, Ribault, S, Nguyen, GB, et al. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. PLoS One, 14, 2019, e0217701.
Lee, G, Oh, SW, Hwang, SS, et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis. PLoS One, 12, 2017, e0177646.
Wang, H, Cordiner, RLM, Huang, Y, et al. Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study. Diabetes Care 46 (2023), 967–977.
Caruso, I, Cignarelli, A, Sorice, GP, et al. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites, 12, 2022, 183.
Usman, MS, Van Spall, HGC, Greene, SJ, et al. The need for increased pragmatism in cardiovascular clinical trials. Nat Rev Cardiol 19 (2022), 737–750.